| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| WB Predicted band size | 22 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human BCL2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于BCCL2抗体的代表性文献(简略版)：
1. **文献名称**：*BCL2 antibody predicts survival in diffuse large B-cell lymphoma*
**作者**：Swerdlow SH, et al.
**摘要**：研究通过免疫组化分析BCL2蛋白在弥漫大B细胞淋巴瘤(DLBCL)中的表达，发现BCL2抗体阳性患者预后较差，提示其作为独立预后标志物的潜力。
2. **文献名称**：*BCL2 overexpression by immunohistochemistry in breast cancer correlates with hormone receptor positivity*
**作者**：Dawson SJ, et al.
**摘要**：利用BCL2抗体检测乳腺癌组织，发现BCL2高表达与雌激素受体(ER)阳性显著相关，可能参与激素依赖性肿瘤的凋亡逃逸机制。
3. **文献名称**：*BH3 profiling with BCL2 family antibodies identifies chemotherapy-resistant cancers*
**作者**：Montero J, Letai A.
**摘要**：开发基于BCL2家族抗体的BH3分析技术，通过检测线粒体凋亡信号预测肿瘤对化疗药物的敏感性，为个体化治疗提供新策略。
*注：以上文献信息为简化示例，实际引用需核对原文DOI及期刊规范格式。*
The BCL2 (B-cell lymphoma 2) antibody is a critical tool in studying apoptosis regulation and cancer biology. The BCL2 gene, first identified in follicular lymphoma due to its translocation t(14;18), encodes an anti-apoptotic protein that prevents programmed cell death by inhibiting mitochondrial outer membrane permeabilization. It interacts with pro-apoptotic proteins like BAX/BAK through conserved BH3 domains, maintaining cellular survival. Overexpression of BCL2 is linked to cancer development, therapy resistance, and poor prognosis in lymphomas, leukemias, and solid tumors.
BCL2 antibodies are widely used in research and diagnostics. In immunohistochemistry (IHC), they help detect BCL2 protein levels to differentiate lymphoma subtypes (e.g., follicular lymphoma vs. reactive hyperplasia) and assess tumor behavior. However, interpretation requires caution, as BCL2 expression varies across tissues and malignancies. Therapeutically, BCL2-targeting drugs like venetoclax (a BH3 mimetic) exploit this pathway, and BCL2 antibodies aid in monitoring target engagement and resistance mechanisms. These antibodies also facilitate studies exploring apoptotic pathways, protein interactions, and novel cancer treatments. Specificity validation remains essential, as cross-reactivity with other BCL2 family members can skew results.
×
